Home > Oncology > ASCO 2021 > Lung Cancer > Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

Presented By
Dr Mark Socinski, AdventHealth Cancer Institute, FL, USA
Conference
ASCO 2021
Trial
Phase 3, IMpower130, IMpower132, IMpower150
An exploratory, post-hoc, pooled analysis of three phase 3 trials with atezolizumab in patients with stage IV non-small cell lung cancer (NSCLC) – IMpower130, IMpower132, and IMpower150 – showed longer overall survival for patients who experience immune-related adverse events. Immune-related adverse events have been reported in up to 80% of patients receiving immune checkpoint inhibitor monotherapy and up to 95% of patients receiving immune checkpoint inhibitor combination therapy [1]. Increasing evidence suggests that the occurrence of immune-related adverse events may be predictive of improved outcomes in cancers such as NSCLC [2]. The phase 3 IMpower130 (NCT02367781), IMpower132 (...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on